News Sentiment

EVO sentiment intelligence

Evotec SE ADR news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 49 Balanced news tone 47 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 2.79 Week of 10 Jul 2026
Weighted tone 49/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

74/100 classification confidence.

Company focus 47

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-4.0% over one week, +2.4% over four weeks, trend inactive, and below fair value.

Latest direct headline Negative

Evotec Shares Fall After TD Cowen Downgrade

Market Reaction

Price moving ahead of tone

57/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 74/100 classification
One-week reaction -4.0% Price reacting lower
Trend fit Trend inactive 2.4% over four weeks
Fair value -46.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 13
Neutral 21
Negative 13

Relevance

Why the article matched

Direct first
Direct company coverage 47
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Investing.com 9
TradingView 7
AD HOC NEWS 6
Stock Titan 5
MT Newswires 3
ad-hoc-news.de 2
Ad Hoc News 2
Ad-hoc-news.de 2

Event Lens

What the news is about

Classified themes
Market update 19
Earnings 18
Analyst action 6
Guidance 3
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 47
Investing.com Direct company coverage

TD Cowen cuts Evotec on customer delays clouding growth outlook

TD Cowen downgraded Evotec SE from "buy" to "hold" and significantly cut its price target after the company's preliminary second-quarter revenue missed estimates and management lowered its full-year guidance. The downgrade is primarily due to persistent customer challenges impact

Tone
Negative 25/100
Event
Earnings
Published
15 Jul 2026 13:13
Source
Investing.com
TradingView Direct company coverage

Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Evotec SE has published a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, distributing the information Europe-wide. JPMorgan Chase & Co. has reported a change in its major holdings in Evotec SE, crossing a threshold on July 10, 2026. The new total

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 12:13
Source
TradingView
Barchart.com Direct company coverage

EVT.D.DX Price History for Evotec Se Stock

This page provides the price history for Evotec Se (EVT.D.DX) stock on Barchart.com, detailing various historical data access options, including daily prices, latest trades, and corporate actions. It also highlights key 52-week metrics, new highs, and new lows, along with how mem

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 02:13
Source
Barchart.com
Investing.com Canada Direct company coverage

Evotec SE (EVO) Q2 2026 Earnings Call Highlights: Navigating Revenue Declines and Strategic ... By GuruFocus

Evotec SE (EVO) reported a significant decrease in H1 2026 group revenues by 19% and projected negative adjusted EBITDA for the full year, leading to a revised guidance. Despite these challenges, the company saw a 28% increase in net sales in its D&PD business, benefited from a l

Tone
Negative 28/100
Event
Earnings
Published
15 Jul 2026 00:17
Source
Investing.com Canada
TradingView Direct company coverage

Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook

Evotec SE announced preliminary unaudited financial results for Q2 and H1 2026 and revised its full-year 2026 outlook. The company now expects lower group revenues and a larger adjusted EBITDA loss than previously guided, with full financial results to be published on August 13,

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 16:13
Source
TradingView
TradingView Direct company coverage

A460RB Bond Profile — Key Metrics

This article provides key metrics for the Evotec SE 2.625% 21-MAY-2033 bond (A460RB), traded on the Frankfurt Stock Exchange. It details the bond's issuer, issue and maturity dates, outstanding amount, face value, minimum denomination, and coupon rate. The profile also includes a

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 14:17
Source
TradingView
TradingView Direct company coverage

Evotec Q2 Earnings Call Highlights

Evotec reported preliminary unaudited results for Q2 and H1 2026, leading to a lowered full-year outlook due to delayed strategic partnership revenue and slower conversion of commercial activity. The company expects a significant decline in revenue and adjusted EBITDA for the fir

Tone
Negative 18/100
Event
Earnings
Published
14 Jul 2026 13:17
Source
TradingView
Stock Titan Direct company coverage

Evotec (NASDAQ: EVO) reduces 2026 outlook amid partnership timing delays

Evotec has reduced its full-year 2026 revenue and EBITDA guidance due to delays in strategic partnerships and milestone phasing. The company now expects revenues of €570-610 million and adjusted EBITDA of -€70 to -105 million, a significant downgrade from previous estimates. Desp

Tone
Negative 38/100
Event
Guidance
Published
14 Jul 2026 10:11
Source
Stock Titan
Investing.com Direct company coverage

Evotec slumps 32% after H1 loss widens, annual outlook slashed

Evotec SE shares plunged 32% after the German life sciences group cut its 2026 outlook, reporting a wider-than-expected first-half loss. The company attributed the shortfall to delays in high-margin strategic partnerships but noted early signs of recovery and ongoing cost-reducti

Tone
Neutral 50/100
Event
Guidance
Published
14 Jul 2026 07:17
Source
Investing.com
scanx.trade Direct company coverage

Evotec cuts FY26 outlook as H1 revenue falls to €300.1 million

Evotec SE has significantly reduced its full-year 2026 financial guidance after reporting lower-than-expected preliminary H1 revenues of €300.1 million. The company now projects Group revenues between €570-610 million and adjusted Group EBITDA between -€70 to -€105 million, a sub

Tone
Negative 10/100
Event
Guidance
Published
13 Jul 2026 21:13
Source
scanx.trade
Moomoo Direct company coverage

Press Release: Ad Hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook

Evotec AG has announced its preliminary financial results for the second quarter and first half of 2026, revealing strong growth across various key financial indicators. The Company reported significant increases in Group revenues, adjusted Group EBITDA, and unpartnered R&D expen

Tone
Positive 70/100
Event
Earnings
Published
13 Jul 2026 20:11
Source
Moomoo
TradingView Direct company coverage

Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook

Evotec has announced preliminary unaudited financial results for Q2 and H1 2026, alongside an updated full-year 2026 outlook due to revised revenue expectations from strategic partnerships. The company now expects lower group revenues and adjusted Group EBITDA than previously gui

Tone
Negative 36/100
Event
Earnings
Published
13 Jul 2026 19:13
Source
TradingView
Stock Titan Direct company coverage

Evotec warns of 2026 loss as it trims revenue and profit guidance

Evotec (NASDAQ: EVO) has announced preliminary unaudited financial results for Q2 and H1 2026, revising its full-year 2026 outlook. The company now forecasts a significant reduction in Group revenues to €570–610 million and anticipates an adjusted Group EBITDA loss of €70 to €105

Tone
Negative 30/100
Event
Earnings
Published
13 Jul 2026 19:13
Source
Stock Titan
ad-hoc-news.de Direct company coverage

Evotec stock reflects biotech ambitions as investors weigh long-term drug discovery pipeline

Evotec (DE0005664809) represents a diversified biotech platform that partners with pharmaceutical companies for drug discovery and development. The German company's model relies on alliance-driven pipelines, generating revenue from research payments, milestones, and potential roy

Tone
Positive 76/100
Event
Earnings
Published
13 Jul 2026 07:38
Source
ad-hoc-news.de
ad-hoc-news.de Direct company coverage

Evotec Forschung Services by Evotec SE - partners tap tailored discovery

Evotec Forschung Services provides integrated drug discovery and development solutions for biotech and pharma partners globally. These services encompass target identification, lead optimization, and preclinical development, leveraging automation, data analytics, and expertise ac

Tone
Neutral 50/100
Event
Analyst action
Published
11 Jul 2026 10:09
Source
ad-hoc-news.de
Ad Hoc News Direct company coverage

Evotec stock reflects strategic repositioning after delisting from Nasdaq

Evotec stock remains in focus after the biotech group withdrew its Nasdaq listing and continues to reposition its business toward higher-value drug discovery partnerships and biologics manufacturing. The company's business model centers on delivering discovery, preclinical, and e

Tone
Positive 71/100
Event
Market update
Published
10 Jul 2026 07:41
Source
Ad Hoc News
Ad-hoc-news.de Direct company coverage

Evotec stock stays anchored by its drug discovery business

Evotec's stock performance remains closely tied to its core drug discovery services and contract research work in Europe and the US. The company, which trades on the Frankfurt market, derives revenue from outsourced research and development, spreading risk across multiple program

Tone
Positive 64/100
Event
Earnings
Published
09 Jul 2026 15:06
Source
Ad-hoc-news.de
Ad-hoc-news.de Direct company coverage

Evotec SE explores strategic options as investor interest grows

Evotec SE, a German biotechnology company, is evaluating strategic options and long-term growth pathways, attracting renewed investor attention. The company specializes in drug discovery and early-stage development, operating a partnered research and development model for both se

Tone
Positive 70/100
Event
Market update
Published
09 Jul 2026 07:37
Source
Ad-hoc-news.de
Ad Hoc News Direct company coverage

Evotec SE outlines its role in global drug discovery. Long-term collaborations support the business

Evotec SE is a German biotechnology company that provides outsourced research and development services to pharmaceutical and biotech partners globally, focusing on early-stage drug discovery and integrated development projects. The company's business model combines fee-for-servic

Tone
Positive 72/100
Event
Market update
Published
08 Jul 2026 21:05
Source
Ad Hoc News
AD HOC NEWS Direct company coverage

Evotec SE highlights collaborative drug discovery model as investors track global biotech demand

Evotec SE, a German biotechnology company, combines contract research with proprietary pipelines, utilizing a collaborative drug discovery model to generate recurring revenue from long-term partnerships and potential milestone/royalty streams. The company's strategy involves offe

Tone
Positive 70/100
Event
Earnings
Published
08 Jul 2026 11:40
Source
AD HOC NEWS
AD HOC NEWS Direct company coverage

Evotec SE outlines its drug discovery model for global investors

Evotec SE is a German biotechnology company that partners with pharmaceutical and biotech groups to discover and develop new drug candidates, acting as a drug discovery and development engine. Its business model focuses on integrated research and development services from early-s

Tone
Positive 76/100
Event
Market update
Published
07 Jul 2026 21:11
Source
AD HOC NEWS
AD HOC NEWS Direct company coverage

Evotec SE develops partnerships in drug discovery. The biotech group expands its global footprint

Evotec SE is expanding its global footprint by building long-term partnerships with pharmaceutical companies and research institutions to translate early-stage science into commercial therapies. The German biotechnology company focuses on integrated research and development, util

Tone
Positive 92/100
Event
Market update
Published
07 Jul 2026 12:13
Source
AD HOC NEWS